LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Home・Aktien・Essa Pharma Inc

Essa Pharma Inc

Geschlossen

1.92

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.83

Max

1.92

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.4M -4M
EPS	-0.14
Angestellte	35
EBITDA	2.2M -6.4M

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	5.7M 90M
Vorheriger Eröffnungskurs	1.92
Vorheriger Schlusskurs	1.92

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

1.7 / 1.72 Unterstützung & Widerstand

Essa Pharma Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Aug. 2025, 23:09 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22. Aug. 2025, 21:23 UTC

Market Talk

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22. Aug. 2025, 21:18 UTC

Market Talk

US Economic Growth Seen Slowing This Year -- Market Talk

22. Aug. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Takes 10% Stake in Intel -- Barrons.com

22. Aug. 2025, 21:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Aug. 2025, 21:03 UTC

Market Talk

Mexican Stocks Close At Record High -- Market Talk

22. Aug. 2025, 20:58 UTC

Market Talk

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22. Aug. 2025, 20:56 UTC

Ergebnisse

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22. Aug. 2025, 20:55 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22. Aug. 2025, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

22. Aug. 2025, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

22. Aug. 2025, 20:41 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22. Aug. 2025, 20:24 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22. Aug. 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22. Aug. 2025, 19:19 UTC

Market Talk

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22. Aug. 2025, 19:10 UTC

Market Talk

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22. Aug. 2025, 19:06 UTC

Market Talk

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22. Aug. 2025, 19:03 UTC

Market Talk

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22. Aug. 2025, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Peer-Vergleich

Kursveränderung

Essa Pharma Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Essa Pharma Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.7 / 1.72Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.